Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world PRN ranibizumab for retinal vein occlusion
ChiCTR2500110658Phase 4Not yet recruiting
- Sponsor
- Hebei Eye Hospital
- Start
- Oct 2025
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of ranibizumab in Vein occlusion (RVO) (2 cohorts), sponsored by Hebei Eye Hospital. Primary endpoint: Mean change in BCVA at 3 months. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
ranibizumab
03
Conditions
Vein occlusion (RVO)
Beyond the preview
Go deeper on ChiCTR2500110658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110658.